NEUROPEPTIDES: RELEVANCE IN TREATMENT OF DEPRESSION AND ANXIETY DISORDERS
NEUROPEPTIDES: RELEVANCE IN TREATMENT OF DEPRESSION AND ANXIETY DISORDERS
复制标题
DOI：
10.1358/dnp.2009.22.6.1395255
复制
发表时间：
2009-07-01
影响因子：
--
通讯作者：
Wilson, Daniel R.
中科院分区：
文献类型：
--
作者：
Madaan, Vishal;Wilson, Daniel R.
抑郁症和焦虑症的病因和病理生理学尚不清楚，但涉及功能失调的单胺能神经传递和功能。目前可用的通过优化单胺能系统发挥作用的抗抑郁药物通常因其疗效或不良反应而受到限制。越来越多的证据表明，一些神经肽，包括 P 物质、促肾上腺皮质激素释放因子、神经肽 Y、加压素和甘丙肽，可能与抑郁和焦虑有关。解剖学、生理学和临床证据的整合表明，单胺能传递的调节是神经肽在这些疾病中发挥作用的最可能的机制。这些神经肽及其受体不仅可以作为治疗抑郁症和焦虑症的潜在治疗靶点，而且还可能有助于增强我们对这两种主要精神疾病的精神病理学的理解。
The etiology and pathophysiology of both depression and anxiety remain unclear, but involve dysfunctional monoaminergic neurotransmission and function. The currently available antidepressant medications that work through optimizing the monoaminergic system are often limited by their tack of efficacy or their adverse effects. There is increasing evidence that some neuropeptides, including substance P, corticotropin-releasing factor, neuropeptide Y, vasopressin and galanin, may have relevance in both depression and anxiety. Integration of anatomical, physiological and clinical evidence suggests that modulation of monoaminergic transmission is the most likely mechanism by which neuropeptides may work in these disorders. These neuropeptides and their receptors may serve not only as potential therapeutic targets for treatment of depression and anxiety, but may also help enhance our understanding of the psychopathology of these two major psychiatric disorders.